

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
INITIAL Survey of the Secretary's Discretionary Advisory Committee on Heritable Disorders in Newborns and Children's Public Health System Assessment ¹	59	1	59	10	590
FOLLOW-UP Survey of the Secretary's Discretionary Advisory Committee on Heritable Disorders in Newborns and Children's Public Health System Assessment	² 30	1	30	2	60
Total	89	89	650

¹ The respondents to the survey will be State and territorial newborn screening programs.

² Up to 30 States and/or Territories will be asked to complete a follow-up survey.

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Amy P. McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2018-12019 Filed 6-4-18; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Tick-Borne Disease Working Group

AGENCY: Office of the Secretary, Office of the Assistant Secretary for Health, Office of HIV/AIDS and Infectious Disease Policy, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) announces the sixth meeting of the Tick-Borne Disease Working Group (Working Group) on June 21, 2018, from 9:30 a.m. to 6:00 p.m., Eastern Time. The sixth meeting will be an on-line meeting held via webcast. The Working Group will focus on subcommittee findings and will review and provide input on the content of the five chapters that will be submitted into the Working Group Congressional Report.

DATES: The on-line meeting will be held on June 21, 2018, from 9:30 a.m. to 6:00 p.m. Eastern Time.

ADDRESSES: This will be an on-line meeting that is held via webcast. Members of the public may attend the meeting via webcast. Instructions for attending this virtual meeting will be

posted prior to the meeting at: <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/index.html>.

FOR FURTHER INFORMATION CONTACT: James Berger, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services; via email at tickbornedisease@hhs.gov or by phone at 202-795-7697.

SUPPLEMENTARY INFORMATION: The Working Group invites public comment on issues related to the Working Group's charge. Comments may be provided over the phone during the meeting or in writing. Persons who wish to provide comments by phone should review directions at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/index.html> before submitting a request via email at tickbornedisease@hhs.gov on or before June 18, 2018.

Phone comments will be limited to three minutes each to accommodate as many speakers as possible. A total of 30 minutes will be allocated to public comments. If more requests are received than can be accommodated, speakers will be randomly selected. The nature of the comments will not be considered in making this selection. Public comments may also be provided in writing. Individuals who would like to provide written comment should review directions at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/index.html> before sending their comments to tickbornedisease@hhs.gov on or before June 18, 2018.

During the meeting, the Working Group will review and discuss the content of the five draft chapters that will be part of the Report to Congress. Persons who wish to receive the draft document should email the tickbornedisease@hhs.gov and request a copy. The document will be available prior to the meeting.

Background and Authority: The Tick-Borne Disease Working Group was established on August 10, 2017, in accordance with section 2062 of the *21st Century Cures Act*, and the Federal

Advisory Committee Act, 5 U.S.C. App., as amended, to provide expertise and review all HHS, DoD and VA efforts related to tick-borne diseases to help ensure interagency coordination and minimize overlap, examine research priorities, and identify and address unmet needs. In addition, the Working Group is required to submit a report to the Secretary and Congress on their findings and any recommendations for improving the federal response to tick-borne disease prevention, treatment and research, and addressing gaps in those areas.

Dated: May 31, 2018.

James Berger,

Office of HIV/AIDS and Infectious Disease Policy, Designated Federal Officer, Tick-Borne Disease Working Group.

[FR Doc. 2018-12045 Filed 6-4-18; 8:45 am]

BILLING CODE 4150-28-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made on the part of Shiladitya Sen, former graduate student, Department of Chemistry and Biochemistry, The Ohio State University (OSU). Mr. Sen engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant R01 GM083114. The administrative actions, including debarment for a period of three (3) years, were implemented beginning on May 16, 2018, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Shiladitya Sen, The Ohio State University: Based on the report of an investigation conducted by OSU and analysis conducted by ORI in its oversight review, ORI found that Mr. Shiladitya Sen, former graduate student, OSU, engaged in research misconduct in research supported by NIGMS, NIH, grant R01 GM083114.

ORI found that Respondent engaged in research misconduct by knowingly and intentionally falsifying and/or fabricating data reported in the following published paper, his Ph.D. thesis, a poster presentation, and his mentor's grant applications submitted to NIGMS, NIH:

- *PNAS* 110(11):4261–4266, 2013 (hereafter referred to as “*PNAS* 2013”); retracted in: *PNAS* 114(37):E7855, 2017 Sep
- Sen, S. “Engineering Proteins for Enhanced Stability using High-Throughput and Combinatorial Methods.” OSU Doctoral Dissertation, 2013 (hereafter referred to as “thesis”)
- poster presented at the Annual Symposium of the Protein Society in 2012 (hereafter referred to as “Poster 2012”)
- R01 GM083114 and R01 GM083114–A1

ORI found that Respondent knowingly and intentionally falsified and/or fabricated gene sequencing and high throughput thermal scanning (HTTS) data for sequence-stability relationship of Rop protein variants in nineteen (19) figures, ten (10) tables, and related text included in a poster presentation, his Ph.D. thesis, and two (2) NIH grant applications.

Specifically, Respondent knowingly and intentionally falsified and/or fabricated:

- Unique sequences and stability data for 1017 active Rop variants in Table 3.1 and provided additional analyses purportedly from those active Rop variants in Table 3.2 and Figures 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, and 3.9 in his thesis and in Figures 6, 7, 17, and 20 in two (2) grant applications
- unique sequences and stability data for active Rop loop variants from four separate mutant libraries, X₄, LX₄, X₄-I, LX₄-I in Tables 5.2, 5.3, 5.4, and 5.5, respectively, and presented additional analyses purportedly from those active Rop loop variants in Figures 5.3, 5.4, 5.5, 5.6, and 5.9 and Table 5.1 in his thesis and in Figure 6 in two (2) grant applications
- figures entitled “analysis of more than 1000 active (folded) core variants,”

“Loop Library: How does loop affect stability?” and “Detailed characterization of loop variants” in Poster 2012

- list of oligonucleotides included in Tables 9.2, 9.3, and 9.4 in his thesis
- ORI also found that Respondent knowingly and intentionally falsified and/or fabricated HTTS data for thermodynamic effects of somatic mutation in antibodies 93F3 and OKT3 in ten (10) figures, two (2) tables, and related text included in *PNAS* 2013 and his thesis.

Specifically, Respondent knowingly and intentionally falsified and/or fabricated HTTS data:

- In Figures 6.2A, 6.2C, 6.3, and 6.6 and Tables 6.2 and 6.3 in his thesis
- also included as Figures 2A, 2C, S2, and S5 and Tables S3 and S4 in *PNAS* 2013

Mr. Sen entered into a Voluntary Exclusion Agreement and voluntarily agreed for a period of three (3) years, beginning on May 16, 2018:

(1) To exclude himself voluntarily from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”);

(2) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

Wanda K. Jones,

Interim Director, Office of Research Integrity.

[FR Doc. 2018–12047 Filed 6–4–18; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center For Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Psychosocial Risk and Disease Prevention.

Date: June 12, 2018.

Time: 8:00 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101.

Contact Person: Weijia Ni, Ph.D., Chief/Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3100, MSC 7808, Bethesda, MD 20892, (301) 594–3292, niv@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Risk Prevention and Health Behavior AREA Review.

Date: June 19, 2018.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: John H Newman, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3222, MSC 7808, Bethesda, MD 20892, (301) 435–0628, newmanjh@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Atherosclerosis, Inflammation, Molecular and Cellular Hematology.

Date: June 25, 2018.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Katherine M Malinda, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4140, MSC 7814, Bethesda, MD 20892, 301–435–0912, Katherine_Malinda@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Integrative Neuroscience.

Date: June 25, 2018.

Time: 12:30 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Ying-Yee Kong, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5185, Bethesda, MD 20892, ying-yeekong@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: